Bagsvaerd, Denmark, 10 November 2015 In accordance with Section 28a of the Danish Securities Trading Act, the company's board members and executives have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company's board members, executives and their associated persons as reported by those persons to Novo Nordisk.
Further information
Media: | ||
Anne Margrethe Hauge | +45 4442 3450 | amhg@novonordisk.com: mailto:amhg@novonordisk.com |
Ken Inchausti (US) | +1 609 514 8316 | kiau@novonordisk.com: mailto:kiau@novonordisk.com |
Investors: | ||
Peter Hugreffe Ankersen | +45 3075 9085 | phak@novonordisk.com: mailto:phak@novonordisk.com |
Daniel Bohsen Melanie Raouzeos Kasper Veje | +45 3079 6376 +45 3075 3479 +45 3079 8519 | dabo@novonordisk.com: mailto:dabo@novonordisk.com mrz@novonordisk.com: mailto:mrz@novonordisk.com kpvj@novonordisk.com: mailto:kpvj@novonordisk.com |
Frank Daniel Mersebach (US) | +1 609 235 8567 | fdni@novonordisk.com: mailto:fdni@novonordisk.com |
http://hugin.info/2013/R/1965833/717797.pdf
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novo Nordisk A/S via Globenewswire